Introduction Within the highly specialized field of drug development, implementing advanced Bioanalytical Services for Rare Disease programs is essential for […]
Process vs. Material Origins Nitrosamine impurities originate from active pharmaceutical ingredient (API) synthetic pathways, degraded raw materials, or chemical interactions
What Is the Difference Between a Nitrosamine Impurity and a Nitrosamine Leachable? Read More »
The Regulatory Imperative for a Peptide Characterization CRO Deliverables Checklist A peptide characterization CRO deliverables checklist serves as a fundamental
Introduction: Biosimilar development is one of the most scientifically rigorous and regulatory-intensive processes in modern pharmaceutical science — and navigating
What is Biosimilar Development? A Step-by-Step Guide from Molecule to Market Read More »
Introduction to Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA The development of clinically successful long-acting parenteral formulations depends on aligning
Encapsulating Hydrophilic vs Hydrophobic APIs in PLGA: Key Formulation Differences Read More »
Assessing the chemical safety of human drug products requires a thorough understanding of potential mutagenic and carcinogenic impurities that fall
Navigating Clinical Translation of CNS Small Molecules Under FDA Fast Track The clinical translation of central nervous system (CNS)-active small
Introduction: In peptide drug development, the quality of your analytical data is only as good as the reference standard anchoring
Identifying and addressing the root causes of failed Extractables and Leachables (E&L) studies has become a critical regulatory requirement for
Introduction Burst release in PLGA formulations is one of the most clinically consequential — and analytically challenging — phenomena in
Understanding Burst Release in PLGA Formulations — Causes, Consequences, and Mitigation Read More »
